{
  "meta": {
    "timestamp": "2025-01-06T14:20:37.785363",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "HilleVax Inc.",
      "symbol": "HLVX",
      "analysis": {
        "historical": {
          "risk_score": 85,
          "key_risks": [
            "Clinical trial failure of lead vaccine candidate HIL-214",
            "Pipeline discontinuation for HIL-214 in infants",
            "Financial and operational strain due to workforce reduction",
            "Regulatory and market challenges in the biopharmaceutical sector"
          ],
          "controversies": [
            "Significant drop in stock price following clinical trial failure",
            "Discontinuation of a major vaccine candidate after advanced clinical development"
          ],
          "environmental_issues": [],
          "social_issues": [
            "70% workforce reduction impacting employee stability and morale"
          ],
          "governance_issues": [
            "Leadership changes during a critical period of operational downsizing"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "A No-Go for HilleVax as Norovirus Vaccine Fails Mid-Stage Test in ...",
              "snippet": "Nonetheless, news of the failed clinical trial dealt a blow to shares of HilleVax, which fell sharply and closed Monday at $1.64 apiece, down 88.3% from Friday's closing price.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.902847+00:00",
              "published_date": null,
              "source_hash": "2a05b8e8436a36c94caf50a98ce362e7"
            },
            {
              "url": "",
              "title": "HilleVax's norovirus vaccine ineffective in large trial of infants",
              "snippet": "HilleVax's candidate, dubbed HIL-214, failed to meet its primary or secondary goals in the Phase 2b study, which tested its ability to prevent moderate or severe norovirus-related acute gastroenteritis. There is no vaccine for norovirus, and HilleVax's candidate was the farthest along in clinical development, according to the company. While ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.902959+00:00",
              "published_date": null,
              "source_hash": "3f19e8d9aabfcfb03e371958a100b62a"
            },
            {
              "url": "",
              "title": "HilleVax to discontinue development of norovirus vaccine for infants ...",
              "snippet": "Shares of HilleVax plunged as much as 87.6% to a record low of $1.75 on Monday after the biotech company said it will discontinue the development of its norovirus vaccine candidate for infants.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883391+00:00",
              "published_date": null,
              "source_hash": "4bc8a7e16348e799b3fca50c1b324e6b"
            },
            {
              "url": "",
              "title": "HilleVax Norovirus vaccine for infants fails in phase 2 clinical trial",
              "snippet": "HilleVax, Inc., a Boston-based vaccine developer, has suspended its clinical trials for its infant norovirus vaccine candidate. Skip to content Skeptical Raptor. Skeptical Raptor uses evidence and science to shred bogus claims about health and medicine. Since 2012. Vaccines.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.902988+00:00",
              "published_date": null,
              "source_hash": "995eb7bfbe100e2d8f6997fa186de148"
            },
            {
              "url": "",
              "title": "HilleVax's stock craters after biotech says it's scrapping a ... - MSN",
              "snippet": "HilleVax Inc.'s stock cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.902998+00:00",
              "published_date": null,
              "source_hash": "841a39be957a89537dc073be8e605d8c"
            },
            {
              "url": "",
              "title": "HilleVax's stock craters after biotech says it's scrapping a norovirus ...",
              "snippet": "HilleVax Inc.'s stock cratered 87% on Monday, after the biotech said it would discontinue the development of a vaccine against norovirus for infants after a trial missed its main goals.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883379+00:00",
              "published_date": null,
              "source_hash": "233ac662b763b5d85b5d109e962fd080"
            },
            {
              "url": "",
              "title": "Reviewing HilleVax (NASDAQ:HLVX) & Zura Bio (NASDAQ:ZURA)",
              "snippet": "HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. About Zura Bio (Get Free Report) ... which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.903017+00:00",
              "published_date": null,
              "source_hash": "e66e8f5313d73538d6366d2d7348479f"
            },
            {
              "url": "",
              "title": "HilleVax, Inc.: HilleVax Reports Topline Data from NEST-IN1 Phase 2b ...",
              "snippet": "The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.903027+00:00",
              "published_date": null,
              "source_hash": "f4f4e143d1de4cdab18f3d2829522e92"
            },
            {
              "url": "",
              "title": "Why Is HilleVax Stock Trading Lower On Monday? - Benzinga",
              "snippet": "Shares of vaccine-developer HilleVax Inc HLVX are down on Monday on a session volume of over 7 million as per data from Benzinga Pro.. Monday, the company released topline data results from the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883401+00:00",
              "published_date": null,
              "source_hash": "93db4637ca96780616e545e2a00a43a2"
            },
            {
              "url": "",
              "title": "ClinicalTrials.gov",
              "snippet": "Glossary. Study record managers: refer to the Data Element Definitions if submitting registration or results information.. Search for terms",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:10.903044+00:00",
              "published_date": null,
              "source_hash": "f648a80f8ff5de6d4aca8f4ead8eea4a"
            },
            {
              "url": "",
              "title": "Why Is HilleVax (HLVX) Stock Down 87% Today?",
              "snippet": "HilleVax (NASDAQ:HLVX) stock is falling hard on Monday following the release of topline data from its Phase 2b clinical trial of HIL-214 in infants. This clinical trial studied the efficacy ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:14.357651+00:00",
              "published_date": "2024-07-08T16:30:00+00:00",
              "source_hash": "a4c98ddcd0e5b5d9c780694f1a899027"
            },
            {
              "url": "",
              "title": "HilleVax, Inc. Announces Workforce Reduction and Leadership Changes",
              "snippet": "HilleVax, Inc ( (HLVX)) just unveiled an announcement. HilleVax, Inc. is reducing its workforce by 70% to cut costs while continuing to pursue the development of its norovirus vaccine and other ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:19.291164+00:00",
              "published_date": "2024-12-05T21:33:00+00:00",
              "source_hash": "35f8c215284b8c50fd6764ac72911e48"
            },
            {
              "url": "",
              "title": "HilleVax, Inc. (HLVX)",
              "snippet": "BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:20:14.357780+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "0cb0ef8317c80768825c2ecc115fc686"
            },
            {
              "url": "",
              "title": "EX-10.10 - SEC.gov",
              "snippet": "This License Agreement (this \"Agreement\") is made effective as of July 2, 2021 (the \"Effective Date\") by and between Takeda Vaccines, Inc., a company incorporated under the laws of Delaware having its principal place of business at 75 Sidney Street, Cambridge, Massachusetts 02139, U.S.A. (\"Takeda\"), and HilleVax, Inc., a company ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966867+00:00",
              "published_date": null,
              "source_hash": "33bf3c80f909d55168da3bd45df516ad"
            },
            {
              "url": "",
              "title": "20 Things You Didn't Know about HilleVax Inc - Money Inc",
              "snippet": "17. Hillevax Inc shows promise for easing economic disruption. Many of us don't stop to think about the impact that a common virus can have on the economics of the world. Hillevax inc seeks to lessen the global annual expense caused by Norovirus, which is approximately $4.2 billion in estimated direct health costs.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966922+00:00",
              "published_date": null,
              "source_hash": "c5fd79e50568bfd985e20c2be2c24a38"
            },
            {
              "url": "",
              "title": "Ropes & Gray Advises HilleVax in Exclusive License Agreement to Acquire ...",
              "snippet": "Ropes & Gray represented HilleVax, Inc. on its exclusive license agreement with Chengdu Kanghua Biological Products Co., Ltd. (Kangh) for rights to Kangh's hexavalent virus-like particle (VLP) vaccine candidate for norovirus outside of Greater China.. As part of the exclusive license agreement, Kangh will supply the VLP vaccine candidate for use in HilleVax's near-term clinical trials ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966933+00:00",
              "published_date": null,
              "source_hash": "03f9bdae5c7eac07c6fcb6027af03701"
            },
            {
              "url": "",
              "title": "HilleVax (Nasdaq:HLVX) - Stock Price, News & Analysis - Simply Wall St",
              "snippet": "HilleVax, Inc. has completed a Follow-on Equity Offering in the amount of $100 million. Sep 21. Chief Medical Officer notifies of intention to sell stock ... for non-US equivalent regulatory forms and sources are used. Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966942+00:00",
              "published_date": null,
              "source_hash": "9ad2bc225d1d5f076076e4dc993856b3"
            },
            {
              "url": "",
              "title": "HilleVax and Kangh Announce Exclusive License Agreement for ... - Nasdaq",
              "snippet": "--HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu Kanghua Biological Products Co., Ltd., a biopharmaceutical ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966950+00:00",
              "published_date": null,
              "source_hash": "ea0c72f96033437ab89feb9d8dadf60d"
            },
            {
              "url": "",
              "title": "HilleVax Inc HLVX Overview - U.S. News",
              "snippet": "HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966957+00:00",
              "published_date": null,
              "source_hash": "0677d8ef7a8bd513086cea977724e7f3"
            },
            {
              "url": "",
              "title": "HilleVax Reports Full Year 2023 Financial Results and ... - Nasdaq",
              "snippet": "--HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966964+00:00",
              "published_date": null,
              "source_hash": "71b751930ebf2766c2afe2a327487a8b"
            },
            {
              "url": "",
              "title": "EX-99.1 - SEC.gov",
              "snippet": "BOSTON, June 8, 2022 - HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2022, highlighted recent program progress, and outlined key upcoming milestones for HIL-214, the company's virus-like ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966970+00:00",
              "published_date": null,
              "source_hash": "efa9b8af67b261dd98c35509fecec295"
            },
            {
              "url": "",
              "title": "HLVX | HilleVax Inc. Stock Overview (U.S.: Nasdaq) | Barron's",
              "snippet": "HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "HilleVax Inc. HilleVax Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:20:15.966977+00:00",
              "published_date": null,
              "source_hash": "544d91b68963fca8a045517e6260a219"
            },
            {
              "url": "",
              "title": "HLVX | HilleVax Inc. Stock Overview (U.S.: Nasdaq) | Barron's",
              "snippet": "Complete HilleVax Inc. stock information by Barron's. View real-time HLVX stock price and news, along with industry-best analysis. ... Market Value: $104.09M: Shares Outstanding: 49.81M: EPS (TTM ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883273+00:00",
              "published_date": null,
              "source_hash": "88c5e8092e44081e33f7fbd20d64cb2a"
            },
            {
              "url": "",
              "title": "HilleVax (Nasdaq:HLVX) - Stock Price, News & Analysis - Simply Wall St",
              "snippet": "HilleVax, Inc. has completed a Follow-on Equity Offering in the amount of $100 million. Sep 21. Chief Medical Officer notifies of intention to sell stock Jun 25. ... Market Average Movement: 6.3%: 10% most volatile stocks in US Market: 17.5%: 10% least volatile stocks in US Market: 3.1%:",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883411+00:00",
              "published_date": null,
              "source_hash": "9f81d1c06829592c7a501b232d4d4a43"
            },
            {
              "url": "",
              "title": "HLVX | HilleVax Inc. Analyst Estimates & Ratings - WSJ",
              "snippet": "HilleVax Inc. analyst ratings, historical stock prices, earnings estimates & actuals. HLVX updated stock price target summary.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883420+00:00",
              "published_date": null,
              "source_hash": "a98d15806abbc76265b173c7039a0000"
            },
            {
              "url": "",
              "title": "HLVX.O - | Stock Price & Latest News | Reuters",
              "snippet": "HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883429+00:00",
              "published_date": null,
              "source_hash": "cc59854d1d9943f60675398ace621800"
            },
            {
              "url": "",
              "title": "HilleVax Inc - Company Profile and News - Bloomberg Markets",
              "snippet": "Company profile page for HilleVax Inc including stock price, company news, executives, board members, and contact information",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883438+00:00",
              "published_date": null,
              "source_hash": "71324dd89cacd3a6b251370c297e1361"
            },
            {
              "url": "",
              "title": "What Makes HilleVax (HLVX) a New Buy Stock - Nasdaq",
              "snippet": "HilleVax, Inc. (HLVX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). ... Since 1988, the full list has beaten the market more than 2X over with an average ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883446+00:00",
              "published_date": null,
              "source_hash": "854b5adbb0b39fb14752aa0b8ca5e193"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "HilleVax, Inc. 75 State Street Suite 100 - #9995 Boston, MA 02109 ... is a\u20acmarket analogue\u20acfor HIL-214 for purposes of estimating your market opportunity.\u20acIn an appropriate location in your prospectus, please expand your discussion to support this statement. ... We face significant competition..., page 39 9. We refer to your disclosure ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:20.883455+00:00",
              "published_date": null,
              "source_hash": "b0e97251171a6089061dfe840a443f22"
            },
            {
              "url": "",
              "title": "HilleVax, Inc. Announces Workforce Reduction and Leadership Changes",
              "snippet": "Don't Miss our Black Friday Offers: HilleVax, Inc ( (HLVX)) just unveiled an announcement. HilleVax, Inc. is reducing its workforce by 70% to cut costs while continuing to pursue the development ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:24.294949+00:00",
              "published_date": "2024-12-05T15:33:00+00:00",
              "source_hash": "fc81737795d944d2cafaf824f6776d33"
            },
            {
              "url": "",
              "title": "HilleVax, Inc. (HLVX)",
              "snippet": "As U.S. stocks experience fluctuations amid anticipation of key inflation data and interest rate decisions, investors are keenly observing market movements for potential opportunities. Penny ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "HilleVax Inc. HilleVax Inc. market competition controversies",
              "retrieved_at": "2025-01-06T21:20:24.295059+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "d9c004d21592a445ba53e455c819f5fe"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "HilleVax Inc. clinical trial failures",
              "rationale": "Investigate potential risks associated with the outcomes of clinical trials for HIL-214",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "HilleVax Inc. regulatory rejections",
              "rationale": "Examine any instances of regulatory hurdles or rejections faced by HilleVax in vaccine approval processes",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "HilleVax Inc. market competition controversies",
              "rationale": "Explore any ethical or social controversies related to HilleVax's competition in the vaccine market",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:20:37.785369",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}